In Vitro Effect of Three-Antibiotic Combinations plus Potential Antibiofilm Agents against Biofilm-Producing Mycobacterium avium and Mycobacterium intracellulare Clinical Isolates

Author:

Batista Sara123,Fernandez-Pittol Mariana123,Nicolás Lorena San3,Martínez Diego3,Rubio Marc45ORCID,Garrigo Montserrat45ORCID,Vila Jordi1236ORCID,Tudó Griselda123ORCID,González-Martin Julian1236

Affiliation:

1. Unitat de Microbiologia, Department de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c/Casanova 143, 08036 Barcelona, Spain

2. ISGlobal Barcelona, Institute for Global Health, c/Rosselló 132, 08036 Barcelona, Spain

3. Servei de Microbiologia, CDB, Hospital Clínic de Barcelona, c/Villarroel 170, 08036 Barcelona, Spain

4. Servei de Microbiologia, Fundació de Gestió de l’Hospital de la Santa Creu i Sant Pau, c/Sant Quintí 89, 08026 Barcelona, Spain

5. Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau), c/Sant Quintí, 89, 08026 Barcelona, Spain

6. CIBER of Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain

Abstract

Patients with chronic pulmonary diseases infected by Mycobacterium avium complex (MAC) often develop complications and suffer from treatment failure due to biofilm formation. There is a lack of correlation between in vitro susceptibility tests and the treatment of clinical isolates producing biofilm. We performed susceptibility tests of 10 different three-drug combinations, including two recommended in the guidelines, in biofilm forms of eight MAC clinical isolates. Biofilm developed in the eight isolates following incubation of the inoculum for 3 weeks. Then, the biofilm was treated with three-drug combinations with and without the addition of potential antibiofilm agents (PAAs). Biofilm bactericidal concentrations (BBCs) were determined using the Vizion lector system. All selected drug combinations showed synergistic activity, reducing BBC values compared to those treated with single drugs, but BBC values remained high enough to treat patients. However, with the addition of PAAs, the BBCs steadily decreased, achieving similar values to the combinations in planktonic forms and showing synergistic activity in all the combinations and in both species. In conclusion, three-drug combinations with PAAs showed synergistic activity in biofilm forms of MAC isolates. Our results suggest the need for clinical studies introducing PAAs combined with antibiotics for the treatment of patients with pulmonary diseases infected by MAC.

Funder

Fundació La Marató de TV3

Ministerio de Economía y Competitividad, Instituto de Salud Carlos III

European Regional Development Fund

Spanish Ministry of Health

Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad

Sociedad Española de Neumología y Cirugía Torácica

Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya

Fundació de Recerca Clínic Barcelona -Institut d’Investigacions Biomèdiques August Pi i Sunyer

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology

Reference53 articles.

1. World Health Organization (2022). Global Tuberculosis Report 2022, World Health Organization.

2. The rise of non-tuberculosis mycobacterial lung disease;Ratnatunga;Front. Immunol.,2020

3. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems;Prevots;Am. J. Respir. Crit. Care Med.,2010

4. Epidemiology of Nontuberculous Mycobacteriosis;Adjemian;Semin. Respir. Crit. Care Med.,2018

5. Non-tuberculous mycobacterial pulmonary disease;Cowman;Eur. Respir. J.,2019

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Treatment for non-tuberculous mycobacteria: challenges and prospects;Frontiers in Microbiology;2024-06-03

2. Biofilms in mycobacterial infection;Clinical Microbiology and Antimicrobial Chemotherapy;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3